Associated Papers
Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.
Chang LC et al.
Clinical Lung Cancer, 2025
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N et al.
Thoracic Cancer, 2025
Patients with Advanced Non-Small Cell Lung Cancer and the EGFR Exon 19 Deletion p.L747 Benefit from Chemotherapy and First-Generation Tyrosine Kinase Inhibitors Compared with Patients with p.E746.
Guan M et al.
Oncotargets and Therapy, 2025
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Gettinger SN et al.
Jco Precision Oncology, 2024
Unravelling the role of PLK1 in tumorigenesis by revealing the mutational landscape of colorectal and lung cancer with PLK1 mutations.
Wang S et al.
Journal of Cellular and Molecular Medicine, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants.
Nishino K et al.
Jto Clinical and Research Reports, 2024
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Grant MJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
Huang LT et al.
Lung Cancer (amsterdam, Netherlands), 2022
Palindromic-assisted self-annealing transcription amplification for reliable genotyping of epidermal growth factor receptor exon mutations.
Yuan R et al.
Biosensors & Bioelectronics, 2021
Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer.
Li C et al.
Translational Lung Cancer Research, 2021
Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.
Huo R et al.
The Oncologist, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
Tokudome N et al.
Bmc Cancer, 2020
Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance.
Batta N et al.
World Journal of Surgical Oncology, 2019
EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing.
Sukari A et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2017